13S150: Draft ACR/EULAR Antiphospholipid Syndrome Classification Criteria

Sunday, November 13, 2022

3:00 PM – 4:00 PM Eastern Time

Location: Terrace Ballroom II&III

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Vinicius Domingues, MD

Florida State university
Daytona beach, FL, United States

Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); aurinia: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Eli Lilly: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); exagen: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); horizon: Advisor or Review Panel Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Janssen: Consultant (Ongoing); Novartis: Consultant (Ongoing); UCB: Consultant (Ongoing)
April Jorge, MD

Massachusetts General Hospital
Boston, MA, United States

Disclosure(s): No financial relationships to disclose

This session will review the new ACR/EULAR Antiphospholipid syndrome (APS) classification criteria, which were developed through an international multidisciplinary effort, with the goal of identifying patients with a high likelihood of APS for research purposes. The methodological approach employs a balance of expert-based and data-driven methods, and involves four phases: item generation (I); item reduction (II); weighting of items and threshold identification (III); and validation (IV). During the session, we will: a) outline the methodology used; b) present the draft or final (if approved by ACR/EULAR by then) criteria while highlighting the novel aspects, as well as the strengths and limitations; and c) encourage the development of collaborative “off-shoot” studies.

Learning Objectives:

Describe the development of the ACR/EULAR Classification Criteria for Antiphospholipid Syndrome (APS)
Recognize the laboratory and clinical manifestations included in the new APS Classification Criteria
Demonstrate the clinical application of the new APS classification criteria

Presentations:

3:00 PM – 3:15 PM Eastern Time

(Draft) ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Methodology
Speaker: Medha Barbhaiya, MD, MPH – Hospital for Special Surgery
3:15 PM – 3:30 PM Eastern Time

(Draft) ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Novel Aspects
Speaker: Stéphane Zuily, MD, PhD – Lorraine University
3:30 PM – 3:45 PM Eastern Time

(Draft) ACR/EULAR Antiphospholipid Syndrome Classification Criteria: World Premiere and Real-world Applications
Speaker: Doruk Erkan, MD, MPH – Hospital for Special Surgery
3:45 PM – 4:00 PM Eastern Time

Q&A